The antibiotics industry has suffered an alarming collapse that has become even more troubling as secondary bacterial infections threaten patients suffering from COVID-19. Why has production of these vital medicines stagnated, and what can be done to address the problem? Economics correspondent Paul Soman reports on why lifesaving drugs don’t necessarily translate to lucrative businesses.
Stream your PBS favorites with the PBS app: https://to.pbs.org/2Jb8twG
Find more from PBS NewsHour at https://www.pbs.org/newshour
Subscribe to our YouTube channel: https://bit.ly/2HfsCD6
PBS NewsHour podcasts: https://www.pbs.org/newshour/podcasts